Trial Profile
An Open-label Proof of Concept Study Regarding the Efficacy and Safety of Dupilumab in the Treatment of Keloids
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Keloids
- Focus Proof of concept; Therapeutic Use
- 20 Jul 2023 Planned End Date changed from 1 Apr 2024 to 1 Dec 2025.
- 20 Jul 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 02 Nov 2022 Planned initiation date changed from 1 Dec 2021 to 1 Dec 2022.